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GPCRs, which form the largest target class in the druggable genome, are crucial for nearly every physiological pro-cess1. Aminergic GPCRs, including histamine, adrenergic, 
dopamine, serotonin, and muscarinic receptors, are of particular 
importance to drug discovery, as they are targeted by one quarter 
of currently approved drugs2,3. Functional selectivity4, or signaling 
bias, is a process whereby GPCR ligands can either activate G pro-
teins or recruit -arrestins to activate select downstream signaling 
pathways at a given receptor5–7. In many instances, one signaling 
pathway is potentially responsible for therapeutic effects whereas 
the other is implicated in side effects8–10. Biased ligands that can 
yield drugs with optimized on-target effects include agonists for 
the D2 dopamine receptor (D2R)8, D1 dopamine receptor (D1R)11, 
angiotensin II type 1 receptor (AT1R)10, -opioid receptor (DOR)12, 
and the -opioid receptor (MOR)9. G protein-biased MOR agonists 
are potentially analgesic and have fewer side effects (for example, 
respiratory depression and constipation13).
The development of biased ligands remains challenging even 
when using high-throughput screening and extensive interrogation 
of the signaling properties of existing ligands10,14–17. Recently, our 
understanding of GPCR ligand recognition and receptor activation 
dynamics as it pertains to biased signaling has been catalyzed by a 
‘golden era’ of GPCR structural biology, with several key aminergic 
receptor structures being published in the last decade18–23. Despite 
this wealth of information, no logical process exists for efficiently 
incorporating insights gleaned from GPCR structures into a design 
strategy for biased-ligand development.
The D2R remains an essential target for antipsychotic drug 
discovery24,25, with the newest atypical antipsychotic drugs (for 
example, aripiprazole, cariprazine) being partial agonists at D2R 
and other receptors26. We previously conducted extensive medici-
nal chemistry exploration of aripiprazole, and although aripip-
razole is a partial agonist at multiple GPCRs26, it shows similar 
potency and efficacy in Gi/o signaling and -arrestin recruitment 
at D2R8,27. Those studies culminated in the discovery of the first 
D2R -arrestin-biased ligands8, which show therapeutic potential 
in animal models of schizophrenia28. Our results suggested that 
D2R -arrestin signaling contributes to the antipsychotic efficacy of 
these drugs, whereas G protein signaling may contribute to extrapy-
ramidal side effects8.
In this study, we used D2R as a model system to identify 
GPCR–ligand contacts that mediate biased signaling, and used 
this information to develop an approach for the structure-based 
drug design (SBDD) of -arrestin-biased ligands for other amin-
ergic GPCRs.
RESULTS
Design of indole-aripiprazole hybrid ligands
We analyzed prior aminergic GPCR structural and mechanistic 
data to identify residues implicated in G protein signaling relative to 
-arrestin signaling. We focused on the orthosteric site, as this is both 
the most common and the most well-conserved binding site for class 
A GPCRs. In the binding pockets of the 1 and 2 adrenergic recep-
tors ( 1AR and 2AR, respectively), transmembrane helix 5 (TM5) 
transduces ligand-induced G protein activation via conserved ser-
ine residues (5.42, 5.43, and 5.46); these findings are supported by 
structural21, mutagenesis29, and NMR30 studies. For the nanobody-
stabilized 2AR crystallized in complex with epinephrine21, the cat-
echol of epinephrine, which is also present on dopamine, forms an 
extensive hydrogen bond network with these conserved TM5 ser-
ines (Fig. 1a), which have been previously posited to form the struc-
tural basis of agonist and partial agonist action31 at 1AR and 2AR. 
D2R also contains TM5 serine residues (Supplementary Results, 
Supplementary Fig. 1a), which, as supported by mutagenesis stud-
ies, contribute to ligand efficacy and overall G protein activation32,33 
and are essential for aripiprazole recognition34.
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Development of biased ligands targeting G protein-coupled receptors (GPCRs) is a promising approach for current drug dis-
covery. Although structure-based drug design of biased agonists remains challenging even with an abundance of GPCR crystal 
structures, we present an approach for translating GPCR structural data into -arrestin-biased ligands for aminergic GPCRs. 
We identified specific amino acid–ligand contacts at transmembrane helix 5 (TM5) and extracellular loop 2 (EL2) responsible 
for Gi/o and -arrestin signaling, respectively, and targeted those residues to develop biased ligands. For these ligands, we 
found that bias is conserved at other aminergic GPCRs that retain similar residues at TM5 and EL2. Our approach provides a 
template for generating arrestin-biased ligands by modifying predicted ligand interactions that block TM5 interactions and 
promote EL2 interactions. This strategy may facilitate the structure-guided design of arrestin-biased ligands at other GPCRs, 
including polypharmacological biased ligands.
Structural clues for binding-pocket residues that mediate arres-
tin recruitment are illuminated by the 5-hydroxytryptamine 2B 
(5-HT2B) receptor structures in complex with ergotamine22 and 
lysergic acid diethylamide35 (LSD; Fig. 1b). In the 5-HT2B–LSD 
structure study, mutation of the conserved hydrophobic EL2 residue 
Leu209 selectively reduced LSD arrestin recruitment by increasing 
ligand on- and off-rates at the receptor. EL2 as a structural motif 
was proposed to function as a ‘lid’ over the binding pocket, thereby 
enhancing ligand residence time and functioning as a major deter-
minant of arrestin recruitment efficacy35. Given that hydrophobic 
residues located in EL2 are relatively well conserved for aminergic 
GPCRs (Supplementary Fig. 1a), we posited that targeting the 
homologous D2 EL2 hydrophobic residue isoleucine 184 (I184EL2) 
may enhance -arrestin recruitment at this receptor, thus leading to 
novel -arrestin-biased ligands.
First, we required a ligand scaffold to test our hypotheses for the 
differential involvement of TM5 and EL2 in biased signaling. We 
recently disclosed -arrestin-biased ligands that are close structural 
analogs of aripiprazole8,36, choosing these as starting points. We also 
required a small fragment predicted to form defined interactions 
with conserved TM5 serines located in the orthosteric site, which 
could be substituted in such a way as to disrupt the TM5 serine 
interactions associated with G protein-dependent activation. Crystal 
structures of the thermostabilized turkey 1AR in complex with 
indole-piperazine clearly illustrate the position of the indole group 
in the orthosteric site near TM5 and EL2, with the indole N–H form-
ing a hydrogen bond with TM5 residue S5.42 (ref. 37; Fig. 1c).
Our design strategy, therefore, was to replace the dichlorophenyl- 
piperazine portion of aripiprazole with the indole-piperazine fragment 
found in the 1AR crystal structure, leading to an indole-aripip-
razole hybrid, compound 1 (Fig. 1d). To generate reliable assump-
tions regarding the binding pose of 1, we constructed hundreds of 
D2R homology models based on the crystal structure of the D3 
receptor19, and subsequently docked compound 1. In the docked D2 
structure, the indole-piperazine portion of 1 occupies the orthosteric 
site, and the indole N–H group forms a hydrogen bond with S1935.42 
(Fig. 1e), consistent with D2 docking of aripiprazole38,39 and the 
1AR crystal structure pose of the indole-piperazine37. Additionally, 
we confirmed 1’s docking pose at TM5 serine mutants, in which 
compound 1’s affinity (Supplementary Fig. 1b) and Gi/o-mediated 
potency (Supplementary Fig. 1c) were selectively decreased at the 
TM5 S193A5.42 mutant.
Indole-aripiprazole hybrid D2R SFSR
Next, we evaluated the structure–functional selectivity relationships 
(SFSR) of indole N-substitutions (for example, methyl, n-propyl, 
i-propyl, benzyl) to 1 (Fig. 2a) intended to disrupt interactions
with TM5. These substitutions introduce steric repulsion between
the ligand and TM5, and are expected to eliminate the S1935.42–
ligand hydrogen bond. To assess ligand bias at G protein versus
-arrestin recruitment pathways, ligands were tested by measur-
ing Gi/o-mediated cAMP inhibition and -arrestin2 recruitment
assays40 conducted in parallel. D2R expression was similar in both
D2 assay platforms (Supplementary Table 1). D2R-mediated
cAMP inhibition, but not D2 -arrestin2 recruitment, was depen-
dent on pertussis-toxin-sensitive Gi/o proteins (Supplementary 
Fig. 2a). Previously, we confirmed that compound 1 is a D2R











































































Figure 1 | Structure-inspired design of indole-aripiprazole hybrid ligands. D2 ligand design based on comparison of three aminergic crystal structures. 
(a) A 2 adrenergic receptor that is nanobody stabilized and has epinephrine bound (4LDO) indicates the catechol of epinephrine is involved in an 
extensive hydrogen bond network with transmembrane (TM) 5 serines. (b) The structure of the 5-HT2B receptor with LSD bound (5TVN) indicates that 
EL2.52 Leu209 forms a hydrophobic cap over ligand, preventing ligand egress. (c) Thermostabilized 1 adrenergic receptor with 4-indole piperazine bound 
(3ZPQ) shows that the indole N–H interacts with Ser5.42 in a hydrogen bond. (d) Design of indole-aripiprazole hybrid compounds by addition of 4-indole 
(blue) replacing the dichlorophenyl (green) of aripiprazole, resulting in compound 1. (e) Docking of 1 in D2 homology model places the unsubstituted 
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Figure 2 | Indole-aripiprazole hybrid D2R SFSR. Structure–functional selectivity relationships (SFSRs) of indole N1-substituted analogs of indole-
aripiprazole hybrids, which lead to either D2 arrestin-bias or antagonism depending on the substitution. (a) Chemical structures of N1-substituted 
indole-aripiprazole hybrids. (b–g) Profiling of indole-aripiprazole hybrids measuring D2 G protein activity (G i/o-mediated cAMP inhibition; red) and 
-arrestin2 recruitment (Tango; blue), normalized to percent quinpirole activity. Data represent n = 5 independent experiments performed in triplicate 
technical replicates and in parallel using the same drug dilutions. (h) SFSR summary for indole-aripiprazole hybrids. Unsubstituted indole (1) shows a 
weak preference for arrestin with respect to quinpirole (bias factor = 2.5; D2 Gi/o; EC50 = 0.98 nM, Emax = 66%, D2 -arrestin2 EC50 = 0.71 nM Emax = 
69%) comparing Gi/o and arrestin activity but N-methyl (2; D2 -arrestin2 EC50 = 6.3 nM, Emax = 36%) and N-n-propyl (3; D2 -arrestin2 EC50 = 81 nM, 
Emax = 32%) show arrestin-bias with no measureable Gi/o activity with respect to quinpirole. Larger substitutions such as N-i-propyl (4) and N-benzyl (5) 
show no activity, and instead act as competitive antagonists. (i) Orthologous assay for D2 G protein activity using D2 Gi1- 2 dissociation as measured 
by BRET, showing partial agonism for 1 (EC50 = 0.49 nM; Emax = 55%) and no activity by 2, compared to quinpirole (EC50 = 1.6 nM). Data represent total 
BRET as calculated using GFP/Rluc ratio. (j) Orthologous assays for -arrestin2 recruitment using BRET measuring Venus-tagged- -arrestin2 and D2long-
tagged Rluc association comparing recruitment by 1 (EC50 = 0.52 nM, Emax = 39%) and 2 (EC50 = 11 nM, Emax = 33%) to quinpirole (EC50 = 13 nM). Data are 
representative and indicate the change in Net BRET with respect to no Venus- -arrestin2 expressed.
and -arrestin2 recruitment activity, whereas 1 shows weak prefer-
ence for arrestin recruitment over Gi/o signaling (bias factor = 2.5) 
relative to quinpirole (Fig. 2c).
As predicted, N-alkyl or aryl substitution completely abolished 
G protein-mediated signaling relative to quinpirole and compound 
1 (Fig. 2d–g). However, the N-methyl (2) and N-n-propyl (3) sub-
stitution retained arrestin-recruitment efficacy, thus exhibiting 
arrestin bias relative to quinpirole (Fig. 2d,e). Interestingly, the 
N-isopropyl (4) and N-benzyl (5) substitutions showed no activ-
ity in both assays (Fig. 2f,g), but still retained appreciable affinity
for D2R (77 and 22 nM, respectively), as measured by radioligand
binding (Supplementary Table 2). In fact, both compounds 4 and
5 are potent and competitive antagonists of quinpirole-stimulated
D2R cAMP inhibition (compound 4 KB = 11.3 nM; compound
5KB = 8.1 nM; Supplementary Fig. 2b,c). The added bulk by
N-isopropyl or N-benzyl likely avoids hydrogen bonding with TM5
and EL2 engagement, pushing on TM5 and preventing activation, 
potentially explaining its antagonist activity. In short, a clear D2R 
SFSR for the indole-aripiprazole hybrids emerged demonstrating 
either arrestin preference or antagonism, dependent on the indole 
N-substitution (Fig. 2h).
In addition, because the interpretation of ligand bias can be
skewed by system-dependent factors (for example, receptor 
reserve, cellular background, or assay platforms), we subjected 
compound 2 to an orthologous assay of D2R G protein activity 
measuring G i1- 2 dissociation by bioluminescent resonance 
energy transfer (BRET). In this assay, compound 2 showed 
no agonist activity, whereas compound 1 was a partial agonist 
with respect to quinpirole (Fig. 2i), recapitulating our findings 
obtained from measuring Gi/o-dependent cAMP inhibition activ-
ity. Further confirmation of arrestin bias, employing an ortholo-
gous platform for arrestin recruitment using BRET, revealed 2 to 
be a potent agonist for arrestin recruitment (EC50 = 17 nM; Emax 
33% of quinpirole Emax response; Fig. 2j). Although no G protein-
mediated agonism could be detected by any method, and therefore 
no bias factor could be formally calculated, we further tested com-
pound 2 as an antagonist of quinpirole-stimulated Gi/o-mediated 
cAMP inhibition (KB = 3.6 nM; Supplementary Fig. 2d) to dem-
onstrate that 2 indeed acts as a competitive antagonist. Finally, 
in light of recent findings that the kinetic context can influence 
bias interpretations35,41, we also profiled the kinetics of signaling 
of 2, which revealed no Gi/o-mediated cAMP inhibition for up to 
90 min (Supplementary Fig. 2e) and robust arrestin recruitment 
peaking between 15–60 min (Supplementary Fig. 2f). In sum-
mary, compound 2 was extensively profiled and was confirmed as 
an arrestin-biased D2 partial agonist.
Simulations predict EL2 engagement for arrestin bias
To identify binding pocket residues that lead certain compounds 
to favor -arrestin recruitment over G protein signaling, we studied 
compounds 1 and 2 by molecular dynamics (MD) simulations. The 
N-methylated compound 2 is incapable of forming a hydrogen bond 
with S1935.42. Like compound 1, compound 2 will likely position its 
indole-piperazine portion in the orthosteric site, with the proto-
nated nitrogen of the piperazine ring forming a salt bridge with the 
conserved D1143.32 in TM3. Less clear, however, is how the effect of 
N-methylation translates to attenuation of G protein signaling with 
retention of -arrestin recruitment. We therefore performed MD sim-
ulations with the head groups of compounds 1 and 2, i.e., without the 
dihydroquinolin-2-one and alkyl linker (Supplementary Fig. 3 and 
Supplementary Table 3). Compounds 1 and 2 are identical aside from 
the head group moiety, and because of the uncertainty in the orienta-
tion of their flexible tail regions, we chose to use the head groups to 
investigate potential structural features that lead to biased signaling.
Simulations of both head groups were initiated from the same posi-
tion in D2R, which was chosen based on the position of 4-(piperazin-1 
-yl)-1H-indole (equivalent to the head group of compound 1) in
the thermostabilized turkey 1AR crystal structure (3ZPQ). These
initial poses incorporated an ionic interaction between the cationic
ammonium of the ligand and D1143.32. The head group of 1 retained
a stable hydrogen bond with S1935.42 throughout each simulation
(Fig. 3a), in agreement with the docked pose of the full-length mol-
ecule. The N-methyl indole moiety of 2, on the other hand, moved
away from TM5 toward the extracellular surface of the D2 orthosteric
site, where it associated closely with I184EL2 (Fig. 3b). These results
—which were consistent across several sets of simulations (Fig. 3c,d
and Supplementary Fig. 4)—indicate that the two head groups,
which differ by only a single methyl group, prefer substantially dif-
ferent positions in the orthosteric site. Compound 1’s head group
prefers interaction with TM5 S1935.42, whereas compound 2’s head
group prefers interaction with EL2 I184. This pose difference sug-
gests that EL2 interaction may be associated with arrestin-biased sig-
naling and TM5 interaction with balanced signaling.
TM5 and EL2 mutants confirm arrestin-biased binding pose
To investigate changes in bias based on ligand contacts with key 
TM5 and EL2 residues, we tested 2 at the S1935.42 and I184EL2 
mutants (Fig. 4a) and quantified Gi/o-mediated cAMP inhibition 
and -arrestin2 recruitment. The design of these mutants reflects 
our previous observations that ligand engagement with S5.42 is 
required for activation of G protein signaling at 2AR, and the 
conserved hydrophobic EL2 residue corresponding to I184EL2 spe-
cifically dampens LSD’s -arrestin recruitment at the 5-HT2B and 
5-HT2A receptors35.
As previously mentioned, the S193A5.42 mutation resulted in a
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Figure 3 | D2R MD simulations predict EL2 engagement for arrestin bias. 
MD simulations of the head groups of compounds 1 (a) and 2  
(b) reveal that -arrestin-biased 2 preferentially interacts with I184 
in EL2 over S193 in TM5. By contrast, 1 maintains a stable hydrogen 
bond with S1935.42 throughout simulation, without interacting 
substantially with I184EL2. Relative positioning of the head groups to 
TM5 and EL2 was tracked by the distance from the ligand indole 
nitrogen to the hydroxyl oxygen of S1935.42 (magenta) and the distance 
from the center of the indole ring to the -carbon of I184EL2 (cyan) for 
compound 1 (c) and 2 (d). The starting pose of the head group simulations, 
equating to the crystal structure of thermostabilized 1AR (3ZPQ) in 
complex with indole 4-(piperazin-1-yl)-1H-indole, is shown 
in light gray, whereas the green ligand and the protein show a 
representative snapshot from simulation. In c and d, thin traces 
are sampled every 100 ps and thick traces are smoothed with a 
1 ns moving average.
the indole N–H forms a hydrogen bond with S1935.42, as found in 
the 1AR crystal structure. Furthermore, we tested the affinity of 
2 at TM5 mutants, and observed no substantial affinity changes 
relative to wild-type D2R for any of the TM5 serine mutations 
(Supplementary Fig. 5a). By contrast, the G protein-mediated sig-
naling of 2 (Fig. 4b) was selectively recovered by the TM5 S193A5.42 
mutation, resulting in balanced signaling between G protein and 
-arrestin2 activity (Fig. 4c) with respect to quinpirole. We rea-
soned that the D2R S193A5.42 mutant creates a hydrophobic space 
for the N-methyl group of 2 to fit, allowing it to recapitulate the 
hydrogen bond between compound 1 and S1935.42 at the wild-
type D2R, leading to G protein signaling. Docking of 2 to the D2R 
S193A5.42 model showed that the steric clash between compound 2 
and S1935.42 in wild-type D2R is abolished at the D2 S193A5.42 mutant 
(Supplementary Fig. 5b). In fact, MD simulations of the head group 
of 2 further support this hypothesis, as at wild-type D2R the head 
group of 2 moves away from TM5 and interacts with I184EL2. In con-
trast, the head group of 2 at the S193A5.42 mutant engages TM5 in a 
pose within the binding pocket that is almost identical to the com-
pound 1 head group in wild-type D2R (Fig. 4d).
Next, we tested compound 2’s arrestin recruitment at the EL2 
I184AEL2 mutation and found that arrestin recruitment by 2 was 
completely abolished in this mutant (Fig. 4e), confirming that EL2 is 
essential for compound 2’s -arrestin recruitment. In fact, I184AEL2 
resulted in no measureable activity of 2 in either G protein signaling 
or arrestin recruitment activity (Fig. 4e). By contrast, -arrestin-
recruitment efficacy for the balanced agonists 1 and quinpirole was 
spared at I184AEL2 (Supplementary Fig. 5c). In addition, 2’s affinity 
at the I184A mutant was spared (Supplementary Fig. 5d), demon-
strating antagonist activity at the D2 I184AEL2 mutant (Fig. 4f and 
Supplementary Fig. 5e). To confirm that mutations of EL2 may be 
directly related to 2’s ligand-binding kinetics, we measured a 2.2-
fold and 8.7-fold increase in the on- and off-rate of 2, respectively, at 
the I184AEL2 mutant compared to wild-type D2R (Supplementary 
Table 4 and Supplementary Fig. 5f), which is consistent with EL2 
mutations decreasing LSD’s residence time at 5-HT2B and 5-HT2A 
receptors35. Furthermore, MD simulations confirm that compound 
2‘s head group is unstable at I184AEL2 D2R and samples many ori-
entations within the binding pocket (Fig. 4g and Supplementary 
Fig. 6a,b), which may partially explain the increased off-rate of 2 at 
the I184AEL2 mutant. Overall, our mutagenesis and computational 
studies confirm that I184EL2 and S1935.42 are critical contacts for 
compound 2’s bias profile.
Rational design of arrestin-biased compounds
Based on the signaling profiles of compounds 1 and 2 at the D2R 
I184EL2A mutant, and MD observations that -arrestin-biased com-
pound 2 preferentially interacts with EL2 over TM5, we designed 
compounds 6 and 7 to test whether additional EL2 engagement 
would lead to superior arrestin recruitment efficacy. Compound 7 
is an analog of 2 containing a 2-methyl substitution to the indole 
ring, which would be expected to engage I184EL2 in a hydrophobic 
contact (Fig. 5a). Compound 6 is the 2-methyl analog of 1, and was 
proposed as a control compound that has similar properties to 7 but 
is predicted to form a hydrogen bond with S1935.42 and demonstrate 
a balanced signaling profile relative to quinpirole. Both 6 and 7 
were synthesized and tested at the D2R for bias (Fig. 5a). Consistent 
with our prediction, 6 displayed no preference for arrestin recruit-
ment over G protein activation, again demonstrating that predicted 
engagement with S1935.42 invariably leads to activation of G protein 
signaling. Unsurprisingly, simulations indicate that the head groups 
of 1 and 6 remain closer to TM5 than do those of 2 and 7, because 
of the presence of a hydrogen bond between S1935.42 and the indole 
N–H of 1 and 6 (Supplementary Fig. 7).
Compound 7, on the other hand, shows a preference for arrestin 
recruitment with a calculated bias factor of 20 relative to quinpirole 
(Fig. 5a), demonstrating much increased arrestin recruitment 
efficacy (Fig. 5b; Emax = 88% of quinpirole) relative to 2. Although 
compound 7 still showed G protein-mediated signaling, its G 
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Figure 4 | D2 TM5 and EL2 mutants confirm arrestin-bias binding pose. (a) The pose resulting from MD simulation of the head group of the arrestin-
biased N-methyl indole-aripiprazole hybrid (2) places the N-methyl indole moiety in contact with I184 on EL2, having moved away from S193 on TM5. 
(b) N-Methyl indole-aripiprazole hybrid 2 only shows arrestin recruitment activity in wild-type (WT) D2. Data represent mean and s.e.m. performed in 
triplicate (Gi/o GloSensor; red; n = 3 independent replicates) and -arrestin2 recruitment (Tango; blue, n = 3 independent replicates; EC50 = 3.7 nM; Emax = 
36%). (c) S193A5.42 transforms arrestin bias of 2 into balanced signaling with respect to quinpirole. Data represent G i/o-mediated cAMP inhibition (Gi/o 
GloSensor; red; n = 3 independent replicates; EC50 = 2.5 nM; Emax = 67%) and -arrestin2 recruitment (Tango; blue, n = 3 independent replicates; EC50 = 2.6 
nM; Emax = 69%). (d) Representative pose of compound 2 head group from simulation at WT and S193A D2R constructs and of compound 1 head group 
from WT D2R simulation. At S193A, 2 moves to a pose almost identical to that of 1 at WT D2. (e) Mutation of EL2 I184 (I184A) completely abolishes 
arrestin recruitment for arrestin-biased ligand 2 (Tango; n = 5 independent replicates). (f) I184A mutation transforms 2 into a D2R -arrestin2 recruitment 
antagonist as measured in Tango (n = 2 independent replicates, in triplicate), as seen by comparing WT D2 (black, IC50 = 6.3 nM) to EL2 I184A (green, 
IC50 = 13 nM). (g) Compound 2 head group is unstable throughout simulation at I184A D2R, sampling many orientations within the 
ligand-binding pocket. Ligand poses are shown for three points in time during a single simulation.
to its -arrestin recruitment activity. To explain the recovery 
in G protein signaling by 7, simulations with the head groups of 
compounds 2 and 7 were performed. Although arrestin-biased 2 
moves the furthest away from TM5, the additional 2-methyl on 7 
hinders this movement and instead shifts the indole ring toward 
TM5 (Supplementary Fig. 7), enough to engage TM5 and activate 
G protein signaling to a degree. Despite this, both 7 and 2 moved 
closer to I184EL2 relative to 1 and 6, potentially explaining their 
arrestin preference.
To provide evidence for this differential EL2 engagement by 7, 
newly synthesized ligands were tested at the I184AEL2 mutant. As 
for compound 2, the I184AEL2 mutation almost completely abol-
ishes the arrestin recruitment activity for compound 7 (Fig. 5c) and 
increases 7’s on- and off-rate by a factor of 6.7 and 6.2-fold, respec-
tively (Supplementary Table 4), indicating that I184 is a key inter-
action for 7’s enhanced -arrestin recruitment efficacy. Although 
the arrestin recruitment of quinpirole and compound 1 are spared 
by the I184AEL2 mutation, compound 6 showed a partial, but not 
complete, loss of arrestin recruitment efficacy, indicating that the 
2-methyl substitution is sensitive to EL2 mutation, but may retain
other ligand–receptor interactions elsewhere in the binding pocket
that lead to arrestin recruitment. To provide support for this notion,
we tested the previously discovered -arrestin-biased ligands UNC
9994 and UNC 9975 (ref. 8) and measured no change in arrestin
recruitment efficacy at the I184AEL2 mutation (Supplementary 
Fig. 8), indicating that -arrestin bias may arise from other
ligand–receptor interactions distinct from EL2. In summary, a
route to attaining -arrestin-biased compounds by modification of
the head group of aripiprazole-type ligands has emerged: remov-
ing interactions with TM5 while enhancing interactions with EL2
can improve -arrestin recruitment efficacy to drive arrestin-biased
signaling, an SFSR succinctly summarized in a heat map of relative
log( /KA) activities (Fig. 5d and Supplementary Table 5).
Prediction and confirmation of polypharmacologic arrestin 
bias
Although aminergic GPCRs bind distinct classes of endogenous 
ligands (e.g., catecholamines, tryptamines, and histamines), the 
orthosteric site encompassing TM5 and EL2 residues is relatively 
well conserved (Supplementary Fig. 1a). We examined whether 
ligand bias resulting from a lack of interaction with TM5 residues 
and the retention of hydrophobic engagement with EL2 is conserved 
for other aminergic GPCRs. Piperazine-containing ligands, such as 
aripiprazole, have promiscuous activity at aminergic GPCRs and 
possess substantial affinity at D3, D4, 5-HT, and - and -adrenergic 
receptors29. We hypothesized that the piperazine-containing ligand 
2 will bind to the orthosteric site in a similar way for those receptors 
and will demonstrate arrestin bias at receptors with residues similar 
to those of D2R at EL2.52 (located 2 residues away from conserved 
disulfide cysteineEL2.50 that are branched aliphatic; for example, leu-
cine and isoleucine) and TM5 5.42 (polar residues that have hydro-
gen bond potential; for example, serine and threonine).
We examined arrestin bias at receptors where 2 has substantial 
affinity (D3R, D4R, 5-HT7R, 5-HT1AR, 5-HT2Rs, 2AR and 1AR; 
Supplementary Table 6). The closely related D3R and D4R contain 
serines at positions 5.42, 5.43, and 5.46 and a branched aliphatic EL2 
residue (isoleucine in D3R, leucine in D4R; Fig. 6a,b). Confirming 
our predictions, 2 demonstrated arrestin bias at D3R (Fig. 6a) and 
D4R (Fig. 6b) compared to quinpirole, with minimal detected G 
protein activity below 1 M. Importantly, the unsubstituted com-
pound 1 demonstrated no preference for either G protein or arrestin 
recruitment at D3R and D4R (Fig. 6a,b). 5-HT7R also has an isoleu-
cine present in EL2 and a serine at TM5 5.42; therefore, we expected 
to observe arrestin bias by 2. Consistent with our prediction, 2 dem-
onstrated full agonist arrestin recruitment activity at 5-HT7R rela-
tive to 5-HT, but surprisingly exhibited 5-HT7R-G s inverse agonist 
activity (Fig. 6c). Similarly, at D3 and D4, 1 showed 5-HT7R agonist 
activity in both G protein and arrestin recruitment. In addition, 
we also tested 2 at 5-HT1AR, which also contains an isoleucine at 
log( /KA) log( /KA)
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Figure 5 | MD-assisted rational design of arrestin-biased compounds. 
(a) Mutagenesis data indicating that 2 requires I184EL2 for -arrestin 
recruitment and MD findings that 2 preferentially interacts with I184EL2 
led to the design of 2-methyl indole derivative 7 to further engage EL2 and 
enhance -arrestin recruitment. Compound 6 is the unsubstituted control 
compound, which can still form a hydrogen bond with S1935.42, and shows 
balanced D2 signaling with respect to quinpirole (bias factor = 1.3; Gi/o 
EC50 = 0.49 nM, Emax = 86%; -arrestin2 EC50 = 0.62 nM, Emax = 78%), but 
compound 7 shows arrestin bias with respect to quinpirole (bias factor 
= 20) in comparison to G i/o-mediated cAMP inhibition (GloSensor; red; 
n = 3 independent replicates; EC50 = 23 nM; Emax = 60%) to -arrestin2 
recruitment (Tango; blue; n = 3 independent replicates; EC50 = 2.9 nM; Emax 
= 78%). (b) 2-Methyl substitution (7, purple; Emax = 78%) shows higher 
D2 -arrestin2 recruitment efficacy compared to compound 2 (blue; Emax 
= 36%) with respect to quinpirole, as measured by Tango. Data were 
normalized to percent quinpirole Emax and represent n = 3 independent 
replicates. (c) Compound 7 interaction with EL2 was confirmed, with the 
I184AEL2 mutation selectively abolishing -arrestin2 recruitment (Tango) 
for biased ligands 2 and 7, but not for balanced 1 (red) and quinpirole 
(black). Compound 6 (orange) shows decreased arrestin recruitment by 
the I184AEL2 mutation, but not complete loss of activity ( -arrestin2 
EC50 = 2.7 nM, Emax = 40%). Data were normalized to quinpirole and 
represent n = 3 independent replicates. (d) Structure–function selectivity 
relationships for the indole-aripiprazole hybrid series as outlined using a 
heat map comparing log log( /KA) activities measuring G protein and 
-arrestin2 recruitment.
EL2.52 and Ser at 5.42. Compound 2 also showed arrestin bias at 
5-HT1AR with a calculated bias factor of 60 with respect to 5-HT,
which exhibits Gi/o preference (Supplementary Fig. 9a). Finally,
we tested 2 at the 5-HT2 receptors, which all contain a Gly at 5.42;
2 showed no Gq-mediated agonist activity at any of these receptors
(Supplementary Fig. 9b–d). However, only at 5-HT2B, which con-
tains a Leu at EL2.52, does 2 show weak arrestin recruitment (~25%
of 5-HT), indicative of weak arrestin bias relative to that of 5-HT
(Supplementary Fig. 9d).
As previously mentioned, the 2AR binding pocket also 
contains TM5 serines at positions 5.42, 5.43 and 5.46, but con-
tains Phe at the EL2.52 residue position (Fig. 6d). Compound 
2 demonstrated G s inverse agonist activity, similar to 5-HT7R, 
but showed no -arrestin recruitment at 2AR, consistent with 
our prediction that smaller aliphatic residues are required for 2 
arrestin recruitment efficacy. Although compound 1 showed Gs 
partial agonism at 2AR, it also showed no arrestin recruitment, 
comparable to 2 (Fig. 6d). A similar profile for 2 was also found 
at 1AR, which also contains a Phe at EL2.52 and a Ser at 5.42 
(Supplementary Fig. 9e). To test the hypothesis that smaller 
aliphatic residues present at EL2.52 may be required for com-
pound 2’s arrestin recruitment efficacy, we attempted to rescue 
compound 2’s arrestin recruitment by mutating 2AR F193EL2.52 
to either alanine, leucine or isoleucine. Although compound 2 
showed no recovered arrestin recruitment activity at any of the 
2AR EL2 mutants (Supplementary Fig. 10a), the 2AR EL2 
mutation substantially reduced arrestin recruitment for the 
full reference agonist isoproterenol (Supplementary Fig. 10b), 


























Gi/o-compound 2 Gi/o-compound 1100
–12 –11 –10 –9 –8 –7 –6 –5
log (compound 2) M
log (compound 2) M log (compound 2) M
EL2
TM5
log (compound 1) M log (compound 1) M log (compound 1) M











–12 –11 –10 –9 –8 –7 –6 –5 –4
–12 –11 –10 –9 –8 –7 –6 –5 –4
–4
–12 –11 –10 –9 –8 –7 –6 –5 –4
–12 –11 –10 –9 –8 –7 –6 –5 –4
–12 –11 –10 –9 –8 –7 –6 –5 –4 –12 –11 –10 –9 –8 –7 –6 –5 –4















































































































































































Figure 6 | Prediction and confirmation of polypharmacological arrestin bias. (a–d) Alignments of D2 TM5 and EL2 residues predict that 2 shows arrestin 
bias at D3 (a), D4 (b) with respect to quinpirole, and at 5-HT7 (c) receptors with respect to 5-HT, in which TM5 and EL2 residues in orthosteric sites are 
well-conserved; the exception to this is 2 (d) with respect to isoproterenol, where 2 shows only inverse agonist activity but no arrestin recruitment.  
G protein signaling was measured by GloSensor, and -arrestin recruitment was measured by Tango performed in parallel. Data represent mean and 
s.e.m. from three independent replicates performed in triplicate. (e) TM5 and EL2 are key contacts in the orthosteric sites of aminergic GPCRs, whereby 
an arrestin-bias template for ligand design can be used to promote EL2 engagement to enhance -arrestin recruitment and preclude TM5 engagement to 
avoid G protein signaling. Structure shown is the base scaffold structure of the aripiprazole hybrid series.
This result confirms our hypothesis that specific interactions by 
2 with smaller aliphatic residues present at EL2, even at other dis-
tinct aminergic receptors, can predict arrestin bias. Here, we show 
that a template can be used to guide biased ligand design at many 
aminergic receptors, where promoting engagement with aliphatic 
residues in EL2 and precluding TM5 interaction can induce an 
arrestin-biased polypharmacological profile (Fig. 6e).
DISCUSSION
Here we illustrate how to design biased ligands by a combined 
computational, structural, biochemical and molecular dynamics 
approach. Importantly, our results identify EL2 as a critical con-
served region of the receptor that can be targeted to enhance arres-
tin bias. We anticipate that this combined strategy will encourage 
the adoption of MD into SBDD projects.
Our results for the D2 I184AEL2 mutation complement our recent 
finding that EL2 is important for arrestin bias and slow binding 
kinetics35. EL2 appears to play an important role in distinguish-
ing between 2AR active and inactive states, whereby the activated 
state of 2AR involves F193EL2.52 and TM7 Y3087.35coming together 
to form a lid over the ligand21. Here we provide evidence that EL2 of 
2AR is also key for arrestin recruitment (Supplementary Fig. 10) 
and that further study of 2AR arrestin recruitment as it relates to 
ligand kinetics is warranted. Apart from aminergic GPCRs, mea-
surements in structural changes in EL2 of rhodopsin reveal that this 
region is important for the retinal isomerization42, as mutations of 
the rod rhodopsin receptor Ile189EL2.52 to proline, which is found at 
EL2.52 at green cone opsin receptors, directly increased decay rates 
of the meta II intermediate state of the receptor43. Taken together, 
these data show that EL2 is an important motif that can ‘lock’ the 
ligand into the binding site, leading to increased ligand residence 
times. This increased residence time apparently promotes arrestin 
recruitment, and this can be exploited for biased drug design.
Structure-inspired drug design supported the hypothesis that 
orthosteric site TM5 residues are engaged not only in ligand rec-
ognition but also in G protein signaling and, further, that these 
interactions can be exploited to modulate biased signaling. Ligand 
contacts with residues in TM5 have been regarded as a ‘trigger’ that 
stabilizes a conformation with a cytoplasmic inward movement of 
TM5 (ref. 44), which in turn moves intracellular loop 2 and TM6 
regions that are involved in G protein activation20,45. Evidence for 
the involvement of D2R TM5 serines in ligand bias is scant, except 
for a study suggesting that Ser5.43 may be involved in ligand- 
dependent arachidonic acid release34. Although we cannot rule out 
alternative downstream effects stemming from targeting EL2 and 
avoiding TM5 interaction (for example, arachidonic acid release, 
pERK1/2), this study is the first to design ligands predicted to avoid 
TM5-dependent G protein activity entirely.
Importantly, our design strategy yielded a ligand with bias at 
multiple related GPCRs. Given that the most clinically effective 
medications for schizophrenia and depression have a complex 
polypharmacological profile46 targeting multiple aminergic GPCRs47 
(i.e., ‘magic shotguns’), it is now possible to design promiscuous 
drugs that manifest arrestin bias at multiple GPCRs by targeting 
conserved interactions within the orthosteric site. We thus pro-
vide a useful template for the rational design of polypharmacologi-
cal drugs incorporating ligand bias (i.e., ‘biased magic shotguns’), 
and successful design will depend on generating optimal predicted 
ligand contacts with EL2. One caveat, though, is that this particu-
lar strategy may be applicable only to aminergic GPCRs. MOR, for 
example, was not proposed to trigger G protein signaling through 
motion of TM5, and thus is not expected to benefit from this SBDD 
algorithm48. Conceivably, our template for biased ligand design 
could also be used to design G protein-biased ligands using the 
reverse approach (i.e., retain TM5 and exclude EL2 engagement); 
such compounds would represent extremely desirable tools to 
dissect the contributions of G protein- versus -arrestin-dependent 
signaling at various aminergic GPCRs to uncover favorable thera-
peutic and side effect profiles.
The wave of GPCR structures has generated excitement largely 
because they promise to accelerate the discovery of new and 
improved drugs49. With knowledge of how ligands can be designed 
to activate specific signaling pathways, it is apparently possible to 
leverage GPCR structures to create biased drugs.
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METHODS
Methods, including statements of data availability and any associ-
ated accession codes and references, are available in the online ver-
sion of the paper.
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ONLINE METHODS
General chemistry procedures. All reagents were purchased from Sigma-
Aldrich or Fisher Scientific. Anhydrous solvents were used unless otherwise 
noted. Analytical HPLC method A: equipment: Agilent 6110 series with UV 
detection at 254 nm; Column: Agilent Eclipse Plus 4.6 mm × 50 mm, 1.8 um 
C18 column. HPLC solvents: A: 0.1% acetic acid in water; B: 0.1% acetic acid 
in methanol, with gradient: 10% to 100% B over 5.0 min, followed by 100% 
B for 2 min, at 1.0 mL/min. Method B: equipment: Agilent Zorbax 300SC-
C18 (5 m) column with UV detection at 254 nm on an Agilent 1200 Series 
LC–MSD TOF machine. HPLC solvents: A: 0.1% acetic acid in water; B: 0.1% 
acetic acid in methanol, with gradient: 1% B for one minute, 1 to 100% B over 
3.0 min, followed by 100% B for 4 min, at 1.0 mL/min. LRMS (low resolution 
mass spectrometry) data were acquired in positive ion mode on an Agilent 
6110 single quadrupole mass spectrometer with electrospray ionization (ESI). 
Nuclear magnetic resonance (NMR) spectra were recorded on either a Varian 
Mercury spectrometer at 400 MHz for proton (1H NMR) and 100 MHz for 
carbon (13C NMR), or a Bruker DRX spectrometer at 600 MHz for proton (1H 
NMR) and 150 MHz for carbon (13C NMR). Preparative HPLC (high pres-
sure liquid chromatography) was performed on an Agilent Prep 1200 series 
with UV detector set to 254 nm, along with a Phenomenex Luna 75 mm ×  
30 mm, 5 um C18 column with a flow rate of 30 mL/min. High resolution mass 
spectrometry (HRMS) data was acquired with an Agilent 1200 Series LC–MSD 
TOF. Medium pressure liquid chromatography (MPLC) was performed on a 
CombiFlash Isco machine. Final compounds had >95% purity as judged by 
analytical HPLC. Indole synthesis schemes and compound purification details 
can be found in Supplementary Note 1.
Drugs and reagents. All compounds and aripiprazole were synthesized as 
described under ‘General chemistry procedures’. Dopamine hydrochloride, 
(−)-quinpirole, (+)-butaclamol hydrochloride, 5-hydroxytryptamine creatine 
sulfate, (−)-isoproterenol bitartrate, and HEPES sodium salt were purchased 
from Sigma-Aldrich (St. Louis, MO). HBSS (10×) was purchased by Invitrogen, 
and fatty-acid free BSA was purchased from Akron Biotech.
Cloning and mutagenesis. Mutagenesis was performed according to 
QuikChange II XL Site-Directed Mutagenesis Kit protocol. Briefly, PCR reac-
tions incorporated wild-type D2 long dopamine receptor (pcDNA3.1, cDNA.
org) or D2 long-V2-tTA (pcDNA3.1) and primers containing the mutation 
of interest. Parental wild-type DNA was digested with DpnI (New England 
BioLabs). PCR products were transformed into supercompetent GC-10 cells, 
and positive clones were selected by ampicillin resistance. Isolated colonies on 
the plates were picked, cultured and prepped using QIAprep Spin miniprep 
and Origene maxiprep kits. DNA was then sequenced (Eton Bioscience) using 
forward (T7) and reverse (BGHreverse and TEV-REV) sequence primers to 
verify mutant DNA sequence.
Cell culture. HEK 293T cells (ATCC CRL-11268; 59587035; mycoplasma free) 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 
10% FBS (Invitrogen) and 0.5% penicillin–streptomycin. HTLA cells express-
ing -arrestin-TEV protease and tTA-driven luciferase (provided by R. Axel 
at Columbia University) were cultured similarly to HEK293T cells except that 
media contained selection antibiotics (100 g/mL hygromycin B and 5 g/mL 
puromycin). Cells were maintained at 37 °C and 5% CO2.
Radioligand binding assays. D2R radioligand binding assays used [3H]N-me-
thyl Spiperone (NMSP; Perkin Elmer, specific activity = 64.1 Ci/mmol). For 
competitive binding experiments, assays used [3H]NMSP concentrations rang-
ing from 0.7–1.3 nM, unlabeled ligand competitor at concentrations ranging 
from 100 M to 1 pM, and membranes resuspended in binding buffer (50 mM 
Tris, 10 mM MgCl2, 0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4). 
Binding assays were incubated at 25 °C for 2 h, and assays were terminated by 
vacuum filtration using a 96-well Filtermate harvester (Perkin Elmer) onto 0.3% 
polyethyleneimine presoaked 96-well filter mats A (Perkin Elmer). Filters were 
washed three times using cold wash buffer (50 mM Tris, pH 7.4), and scintil-
lation cocktail (Meltilex) was melted onto dried filters. Radioactivity displace-
ment was measured using a Wallac Trilux Microbeta counter (Perkin Elmer). 
Counts per minute (c.p.m.) were plotted as a function of unlabeled ligand con-
centration and the Ki was calculated using the One-site-Fit Ki using 5.0. Data 
were normalized to the top (100%, no competitor) and bottom (0%, nonspe-
cific binding defined as 5 M (+)-butaclamol) to represent percent displace-
ment. For radioligand binding assays at all other receptors, procedures were 
similar to those described above, except the radioligand used and membrane 
sources. For a list of these binding assays, refer to procedures at https://pdspdb.
unc.edu/pdspWeb/ for the National Institute of Mental Health Psychoactive 
Drug Screening Program (NIMH PDSP).
For the determination of kon and koff for unlabeled compounds 2 and 7 
membranes of D2 wild-type and I184AEL2 were incubated with at least two 
concentrations of [3H]NMSP (range 0.08-0.35 nM) and several concentra-
tions of 2 or 7 (range 1 M to 320 pM). On- and off-rates of [3H]NMSP at D2 
wild-type and I184AEL2 were previously determined and used to estimate the 
kon and koff rates of 2 and 7 using “Kinetics of competitive binding” equation 
in Graphpad Prism 5.0 by Motulsky and Mahan (1984)50.
Gi/o-mediated cAMP inhibition assay. To measure Gi/o-mediated cAMP 
inhibition, HEK293T cells were co-transfected in a 1:1 ratio with receptor 
and a split-luciferase-based cAMP biosensor (GloSensor; Promega). After at 
least 24 h, transfected cells were plated in poly-lysine coated 384-well white 
clear-bottom cell culture plates with DMEM containing 1% dialyzed FBS at 
a density of 15,000 cells per 40 L per well and incubated overnight. On 
the day of assay, drug dilutions were prepared in filtered fresh assay buffer 
(20 mM HEPES, 1× HBSS, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) at 3× 
and 10 L per well was added to cells containing 20 L/well of assay buffer. 
Drug solutions used for G protein-mediated cAMP assays were exactly the 
same as those used for Tango assays to allow relative within-experiment bias 
comparisons. After plates were allowed to incubate with drug for 15 min, 
10 L per well of 1 M (final concentration) forskolin and GloSensor sub-
strate was added. Luminescence counts per second (LCPS) were quantified 
after 15 min using a TriLux microbeta (Perkin Elmer) luminescence counter. 
LCPS were plotted as a function of drug concentration and normalized to 
percent quinpirole with 100% as the quinpirole cAMP inhibition Emax and 
0% as the forskolin-stimulate cAMP baseline. Data were analyzed using 
log (agonist) vs. response in GraphPad Prism 5.0 (Graphpad Software Inc., 
San Diego, CA).
Tango -arrestin recruitment assays. The human D2Long Tango construct 
was designed, and assays were performed as previously described8,40. HTLA 
cells expressing TEV fused -arrestin2 were transfected with D2 Tango con-
struct. For D3 and D4 Tango constructs, GRK2 was co-transfected in a 1:10 
ratio of GRK2:receptor. After at least 24 h, cells were plated in DMEM sup-
plemented with 1% dialyzed FBS (dFBS) in poly-L-lysine-coated 384-well 
white clear-bottom cell culture plates at a density of 15,000 cells/well in total 
of 40 L. After at least 6 h, media was decanted, and cells were supplemented 
with 40 L of 1% dFBS DMEM, and drug solutions (3×) prepared in drug 
buffer (1× HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) 
were added (20 L per well) for overnight incubation. Drug solutions used 
for Tango assay were exactly the same as those used for G protein-mediated 
cAMP assays to allow relative within experiment bias comparisons. The 
next day, media and drug solutions were decanted and 20 L per well of 
BrightGlo reagents (Promega, 1:20 dilution in drug buffer) was added. The 
plate was incubated for 20 min at room temperature in the dark before being 
counted using Wallac TriLux microbeta (Perkin Elmer). LCPS were plot-
ted as a function of drug concentration, normalized to percent quinpirole 
with 100% as the quinpirole Emax and 0% as the baseline, and analyzed using 
log (agonist) vs. response in GraphPad Prism 5.0 (Graphpad Software Inc., 
San Diego, CA).
Bioluminescence resonance energy transfer (BRET) assays. To measure 
D2-mediated -arrestin2 recruitment, HEK293T cells were co-transfected in a 
1:1:15 ratio with D2Long containing C-terminal renilla luciferase (RLuc), GRK2, 
and Venus-tagged N-terminal -arrestin2. After at least 24 h, transfected 
cells were plated in poly-lysine coated 96-well white clear bottom cell culture 
plates in plating media (DMEM containing 1% dialyzed FBS) at a density of 
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40,000–50,000 cells in 200 L per well and incubated overnight. The next day, 
media was decanted and cells were washed twice with 60 L of drug buffer (1× 
HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4); then, 60 L of 
drug buffer was added per well. Drug stimulation was performed with addition 
of 30 L of drug (3×) per well and incubated at various time points. At 15 min 
before reading, 10 L of the RLuc substrate, coelenterazine h (Promega, 5 M 
final concentration) was added per well, and plates were read for both lumi-
nescence at 485 nm and fluorescent eYFP emission at 530 nm for 1 s per well 
using a Mithras LB940. Plates were read for multiple time points up to 60 min 
after drug addition. The BRET ratio of eYFP/RLuc was calculated per well, and 
the net BRET ratio was calculated by subtracting the eYFP/RLuc per well from 
the eYFP/RLuc ratio in wells without Venus- -arrestin present. The net BRET 
ratio was plotted as a function of drug concentration using Graphpad Prism 5 
(Graphpad Software Inc., San Diego, CA).
To measure D2R-mediated G i1- 2 dissociation, we carried out the same 
procedures as those for D2-mediated -arrestin2 recruitment, except that 
HEK293T cells were co-transfected in a 1:5:5:5 ratio of G i1-RLuc, G 1, 
GFP2-G 2, and D2long, respectively. G i1-RLuc, G 1 and GFP2-G 2 constructs 
were generously provided by M. Bouvier (Université de Montréal). G i1- 2 
dissociation BRET2 assays used 10 L of the RLuc substrate Coelenterazine 
400a (Nanolight, 5 M final concentration), incubated for 10 min, and read 
for luminescence at 400 nm and for fluorescent GFP2 emission at 515 nm for 
1 s per well using a Mithras LB940. The ratio of GFP2/RLuc was calculated per 
well and plotted as a function of drug concentration using Graphpad Prism 5 
(Graphpad Software Inc., San Diego, CA).
Bias calculation. Transduction coefficients (log ( /KA)) were calculated using 
the Black and Leff operational model in Graphpad Prism 5.0, where  is agonist 
efficacy and KA is the equilibrium dissociation constant. Using quinpirole as the 
full agonist reference, transduction coefficients for Gi/o activity and -arrestin2 
recruitment were calculated and averaged across experiments. Calculation of 
bias factors used the method by Kenakin et al.51, where the log( /KA) was 
calculated relative to the reference and the log( /KA) was calculated by sub-
tracting the -arrestin2 from the Gi/o transduction coefficient.
Homology modeling and docking. Construction and selection of the D2 
dopamine receptor homology model was as described52. Briefly, 400 D2 models 
were built with MODELLER 9v8 (ref. 53), using the crystal structure of the D3 
dopamine receptor (PDB ID 3PBL) as the template19. The sequence alignment 
between D2 and the D3 template were generated using PROMALS3D. The final 
D2 model was chosen based on its ability to enrich 85 known, diverse, and high-
affinity ligands (taken from the ChEMBL10 database) against a background 
of property-matched decoy molecules and experimentally tested nonbinders 
from ChEMBL10. The model’s ability to recognize both antagonists and biased 
agonists were tested prospectively in multiple virtual screening campaigns, 
and, based upon this performance, we decided to use the same model in this 
study to dock ligands with various functional profiles. Here, we used DOCK3.7 
to dock substituted indole-aripiprazole hybrid ligands into the binding site of 
the D2 model, as in previously published protocols. Aripiprazole and indole-
aripiprazole hybrid ligands were protonated using the pKa prediction tool built 
into Marvin from ChemAxon (Marvin version 5.5.1.0; ChemAxon, 2011). The 
flexible-ligand sampling algorithm in DOCK3.7 uses a graph-matching tech-
nique to superimpose atoms of the docked molecule onto binding site match-
ing spheres, which represent favorable positions for individual ligand atoms. 
Complementarity to the protein of each ligand pose is scored using a physics-
based scoring function consisting of receptor–ligand electrostatic and van der 
Waals interaction energies, using modified versions for DOCK of the AMBER 
potential and QNIFFT point-charge Poisson-Boltzmann electrostatics models, 
respectively. Energies were corrected for context-dependent ligand desolva-
tion using a variation of AMSOL desolvation energies. Individual ligands were 
sampled until a maximum of 20,000 favorable conformations were found and 
scored. The ability to save any number of top poses of a molecule was used here 
to examine all possible binding orientations.
System setup for molecular dynamic (MD) simulations. MD simula-
tions of the dopamine D2 receptor (D2R) were based on a homology model  
constructed from the crystal structure of the dopamine D3 receptor com-
plexed to the antagonist eticlopride (PDB ID 3PBL)19. The resulting model was 
simulated in four conditions: in complex with the head group of compounds 
1, 2, 6 and 7, i.e. with the dihydroquinolin-2-one and alkyl linker removed 
(Supplementary Fig. 3). The ammonium nitrogen was methylated in order 
to maintain the same atom-types as the full-length molecules for simulation. 
Placement of ligands was guided by the crystal structure of thermostabilized 
turkey 1-adrenoceptor (3ZPQ)37, which is complexed to 4-(piperazin-1- yl)-
1H-indole (equivalent to the head group of compound 1).
Hydrogen atoms were added using Prime (Schrödinger Inc.), and protein 
chain termini were capped with the neutral groups acetyl and methylamide. 
Titratable residues were left in their dominant protonation state at pH 7.0. All 
aspartate residues were deprotonated, as is expected in the inactive state of 
GPCRs, the tertiary amine of the ligands was protonated.
The prepared protein structures were aligned on the transmembrane helices 
to the Orientation of Proteins in Membranes (OPM)54 structure of PDB 3PBL, 
and internal waters added with Dowser55. The structures were then inserted 
into a pre-equilibrated palmitoyl-oleoyl-phosphatidylcholine (POPC) bilayer, 
and solvated with 0.15 M NaCl in explicitly represented water, then neutralized 
by removing sodium ions. Final system dimensions were approximately 76 × 
72 × 88 Å3, including about 108 lipids, 14 sodium ions, 25 chloride ions, and 
9047 water molecules.
Molecular dynamics simulation protocol. We used the CHARMM36 
parameter set for protein molecules, lipid molecules, and salt ions, and the 
CHARMM TIP3P model for water; protein parameters incorporated CMAP 
terms56. Parameters for ligands were generated using the CHARMM General 
Force Field (CGenFF)57 with the ParamChem server (https://paramchem.
org), version 1.0.0. Parameters associated with the dihedral term shown in 
Supplementary Figure 4 were refit using Paramfit58 to the results of quan-
tum mechanical calculations performed in Gaussian09. Full parameter sets 
are available upon request. MD simulations were performed on GPUs using 
the CUDA version of PMEMD (Particle Mesh Ewald Molecular Dynamics) in 
Amber14 (ref. 59).
Prepared systems were minimized, then equilibrated as follows: The sys-
tem was heated using the Langevin thermostat from 0 to 100 K in the NVT 
ensemble over 12.5 ps with harmonic restraints of 10.0 kcal·mol−1·Å−2 on the 
nonhydrogen atoms of lipid, protein and ligand, and initial velocities sampled 
from the Boltzmann distribution. The system was then heated to 310 K over 
125 ps in the NPT ensemble with semi-isotropic pressure coupling and a pres-
sure of one bar. Further equilibration was performed at 310 K with harmonic 
restraints on the protein and ligand starting at 5.0 kcal mol−1·Å−2 and reduced 
by 1.0 kcal mol−1·Å−2 in a stepwise fashion every 2 ns, for a total of 10 ns of 
additional restrained equilibration.
We performed five simulations of D2R bound to the head group of 1, and 
five of D2R bound to the head group of 2. We also performed simulations of the 
head groups of compounds 6 and 7 bound to D2R, and the head group of com-
pound 2 bound to both S193A and I184A D2R mutant models (Supplementary 
Table 5). These simulations were conducted in the NPT ensemble at 310 K 
and 1 bar, using a Langevin thermostat and Monte Carlo barostat. In each of 
these simulations, we performed 5 ns of unrestrained equilibration followed 
by a production run of 250–350 ns.
Simulations used periodic boundary conditions, and a time step of 
2.5 fs. Bond lengths to hydrogen atoms were constrained using SHAKE. 
Nonbonded interactions were cut off at 9.0 Å, and long-range electrostatic 
interactions were computed using the particle mesh Ewald (PME) method 
with an Ewald coefficient  of approximately 0.31 Å and B-spline interpola-
tion of order 4. The FFT grid size was chosen such that the width of a grid 
cell was approximately 1 Å.
Molecular dynamics simulation analysis. Trajectory snapshots were saved 
every 100 ps during production simulations. Trajectory analysis was performed 
using VMD60 and CPPTRAJ61, and visualization was performed using VMD. 
Trajectories were aligned to the D2 inactive state homology model on all trans-
membrane helix C  atoms. Two metrics were used to determine the position 
of the head groups of 1 and 2 in relation to TM5 and EL2 during simulation: 
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(1) the distance between the indole nitrogen atom of the head group and the 
side chain oxygen atom of S1935.42 and (2) the distance from the midpoint of 
the indole C8–C9 bond and the C  atom of I184EL2 (Fig. 3 and Supplementary 
Fig. 4). The distance from the ligand cationic nitrogen to D1143.32 was also 
monitored to ensure that this interaction essential to D2 agonists was main-
tained. To allow comparison of the head groups of 1, 2, 6 and 7, the distance 
between the nearest ligand heavy atom and the side chain oxygen of S193, and 
the distance between the nearest ligand heavy atom and C  of I184 were used 
(Supplementary Fig. 7).
Code availability. The DOCK3.6 program is freely accessible at http://dock.
compbio.ucsf.edu/DOCK3.6/ to academic labs.
Life Sciences Reporting Summary. Further information on experimental 
design and reagents is available in the Life Sciences Reporting Summary.
Data availability. Generated and analyzed data sets that support the find-
ings of this study are available from the corresponding authors upon 
reasonable request.
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